Home

Hyperthermia

Overview


1. 6/5/02 Experimental and Unconventional Search on Hyperthermia
   
   
2. 5/8/02 Hyperthermia in oncology. Int J Hyperthermia 2001 Jan-Feb;17(1):1-18 PMID: 11212876 The clinical application of hyperthermia with increase of tissue temperatures (range 40-44 degrees C) has been integrated in multimodal anti-cancer strategies. This review describes selected phase I or II (n = 17) and phase III trials (n = 16) investigating the effect of hyperthermia combined with radiotherapy (n = 10 trials), chemotherapy (n = 15 trials), or both (n = 8 trials) in a total of more than 2200 patients. The trials were performed in a variety of solid tumours (e.g. melanoma, head and neck cancer, breast cancer, cancer of the gastrointestinal or urogenital tract, glioblastoma, sarcoma) in paediatric or adult patients. Profound research has produced a scientific basis for the simultaneous application of hyperthermia in combination with ionizing radiation and/or systemic chemotherapy. Hyperthermia is becoming more accepted clinically, due to the substantial technical improvements made in achieving selected increase of temperatures in superficial and deep-seated tumours.
   
   
3. 5/8/02 [Addition of hyperthermia. Heat potentiates cancer therapy] MMW Fortschr Med 2001 Jun 21;143(25):28-32 PMID: 11468993 It has been unequivocally demonstrated that hyperthermia (40-44 degrees C) has an potentiating effect on radiotherapy and chemotherapy. Technical improvements have facilitated the application of both local and whole-body hyperthermia, and have thus made this form of treatment available to large numbers of patients. Randomized phase III studies performed in patients with breast cancer, malignant melanoma and cervical cancer have convincingly confirmed the increased efficacy of the combination of radiotherapy with local or regional hyperthermia in comparison with radiotherapy alone
   
   
4. 5/8/02 Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol 2001 Jun;27(4):340-2 PMID: 11417976 It has been demonstrated in vitro and in vivo that hyperthermia can enhance the cytotoxicity of some chemotherapeutic agents. The in vivo studies have demonstrated that the thermal advantage is maximized at mild temperatures such as at 40.5--43 degrees C. Thermo-chemotherapy is widely applied in limb perfusion and intraperitoneal chemotherapy. Hypoxia in solid tumours leads to resistance to most anticancer drugs and appears to accelerate malignant progression and increase metastasis. The recent development of new drugs highly toxic to hypoxic cells may bring new strategies in anticancer treatments and move this condition from being a problem to a new tool in cancer control.
   
   
5. 5/8/02 Relationship between thermal parameters and tumor response in hyperthermia combined with radiation therapy Int J Clin Oncol 2001 Jun;6(3):138-42 PMID: 11706783
   
   
6. 5/8/02 A case of locally advanced breast cancer treated with hyperthermia in combination with radiotherapy Gan To Kagaku Ryoho 2001 Oct;28(11):1746-8 PMID: 11708024 59-year-old woman was admitted to our hospital because of massive bleeding from a right breast tumor. The breast tumor had existed for ten years occupied the entire right breast (23 x 20 cm), its central part forming an ulcer 17 x 15 cm in size. Radiotherapy to the right breast and medication with tamoxifen were started, after which five courses of CMF chemotherapy were given. The tumor decreased to 16 x 14 cm, and hyperthermia to the right breast was performed for a total of 87 sessions from January 1999. The irregular protruding portion of the ulcer caused the necrosis, and was sloughed off about one month after hyperthermia. No viable tumor cells were observed in a biopsy taken at 5 months after the start of treatment (40 sessions). A total of 87 hyperthermia sessions were performed, and the ulcer disappeared. For 15 months after the end of hyperthermia, the patient showed a continuous CR. Hyperthermia in combination with radiotherapy or chemotherapy for breast cancer may produce a remarkable effect as in the present case, and may become one choice for medical treatment of locally advanced or recurrent breast cancer
   
   
7. 5/8/02 Dosimetry and techniques for simultaneous hyperthermia and external beam radiation therapy Int J Hyperthermia 2001 Jan-Feb;17(1):48-62 PMID: 11212880 An increased biological effect is realized when hyperthermia and radiation therapy are combined simultaneously. To take advantage of this effect, techniques have been developed that combine existing hyperthermia devices with a linear accelerator. This allows concomitant delivery of either ultrasound or microwave hyperthermia with photon radiation therapy
   
   

   ---

   Hyperthermia Sensitizers
   
   NOTE: Quercetin is an AVAILIABLE supplement in your health food store
   
   
8. 5/8/02 Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia Melanoma Res 2001 Oct;11(5):469-76 PMID: 11595883 Hyperthermia produces regression of human cancer. Because hyperthermia has produced only limited results, attention has focused on searching for substances able to sensitize tumour cells to the effects of hyperthermia. The flavonoid quercetin has been reported to be a hyperthermic sensitizer in ovarian and uterine cervical tumours and in leukaemia. Quercetin and tamoxifen inhibit melanoma cell growth
   
   
9. 5/8/02 Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation Acta Oncol 2001;40(4):497-503 PMID: 11504310
   
   
10. 5/8/02 Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia 2001 Jul-Aug;17(4):347-56 PMID: 11471985 Tumour hyperthermia, although potentially a powerful therapeutic agent and radiation sensitizer, is hindered by a number of considerations including inhomogeneous heating of deep seated tumours due to energy deposition and perfusion issues. One solution is to design hyperthermia sensitizers to amplify the effects of hyperthermia, particularly at cold spots within the tumour undergoing treatment. This study examined the use of Quercetin, a flavonoid drug shown previously to antagonize the expression of HSP72 and induce apoptosis as a sensitizer of prostate cancer growth in vivo. Quercetin dose-dependently suppressed PC-3 tumour growth in vitro and in vivo. When combined in a treatment protocol with hyperthermia, quercetin drastically inhibited tumour growth and potently amplified the effects of hyperthermia on two prostate tumour types
    
    
11. 5/8/02 Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors. Radiother Oncol 2001 Aug;60(2):147-54 PMID: 11439209 CONCLUSIONS: We conclude that the combination of CA-4 and hyperthermia is a potent therapeutic option for BT4An tumors, but the selection of adequate time intervals between CA-4 and hyperthermia are imperative to obtain tumor response
    
    

    ---

    Liver Tumors
    
    
12. 5/8/02 Targeting liver tumors with hyperthermia: ferromagnetic embolization in a rabbit liver tumor model. J Surg Oncol 2001 Sep;78(1):22-9; discussion 30-1 PMID: 11519064 Ferromagnetic embolization hyperthermia (FEH) consists of arterially embolizing liver tumors with ferromagnetic particles, and then applying an external alternating magnetic field to generate hysteretic heating within the embolized particles. The objective of this study was to assess the ability of FEH to selectively target liver tumors with hyperthermia CONCLUSIONS: Hepatic arterial infusion of lipiodol containing ferromagnetic particles can result in excellent targeting of liver tumors with hyperthermia on the subsequent application of an external alternating magnetic field. The promising results of this study warrant further investigation of FEH as a potential treatment for advanced liver cancer
    
    
13. 5/8/02 Treatment of experimental rabbit liver tumours by selectively targeted hyperthermia. Int J Hyperthermia 2002 Mar-Apr;18(2):117-28 PMID: 11911482 Experimental rabbit liver tumours were preferentially heated to therapeutic temperatures without compromising the surrounding normal hepatic parenchyma. This was achieved by the use of hepatic arterially infused ferromagnetic microspheres that heat as a result of magnetic hysteresis loss when exposed to an alternating magnetic field
    
    
14. 5/8/02 Status of hyperthermia in the treatment of advanced liver cancer. J Surg Oncol 2001 Aug;77(4):259-69 PMID: 11473375 The vast majority of patients with malignant liver tumors have inoperable disease. These patients must rely on chemotherapy, radiotherapy, and various locoregional treatments. Although these treatments have demonstrated encouraging response rates, symptom palliation and occasional down staging of tumors, their impact on survival is minor. As a result there has been renewed interest in hyperthermia as a treatment option. This study reviews the current modalities of hyperthermia in terms of clinical results, side effects, limitations, and therapeutic standing
    
    
15. 5/8/02 Laser-induced interstitial thermotherapy of liver metastases in an interventional 0.5 Tesla MRI system: technique and first clinical experiences J Magn Reson Imaging 2001 May;13(5):729-37 PMID: 11329194 Laser-induced interstitial thermotherapy (LITT) surveyed by magnetic resonance imaging (MRI) has been shown to be effective in various applications. The laser treatment of colorectal liver metastases usually requires a separate device (e.g., ultrasound or CT) to position the laser applicator. In this study, we used an interventional 0.5 T MRI system, allowing both the navigation to the target tissue and on-line thermometry. Laser irradiation was performed using a near-infrared laser source combined with a cooled laser light guide. We treated 20 patients exhibiting a total of 58 colorectal liver metastases. Clinically relevant complications did not occur. No residual tumor was observed after laser irradiation in all metastases with a diameter below 2 cm. Metastases with a mean diameter between 2 and 3 cm demonstrated total necrosis in 71%, while in larger tumors this proportion decreased to 46% (diameter, 3-4 cm) and 30% (diameter, >4 cm), respectively. We conclude that LITT, guided by the employed interventional MRI system, is feasible and safe. The results suggest a more aggressive treatment, especially for larger metastases
    
    
16. 5/8/02 Update of laser-induced thermotherapy for liver tumors. Hepatogastroenterology 2001 Mar-Apr;48(38):330-2 PMID: 11379302 Surgical resection generally offers the only chance of long-term survival for patients with primary or secondary liver tumors. Difficulties relating to the stage of the tumor, the extent of underlying liver cirrhosis and the general condition of the patient make this technique unsuitable for the majority of patients. Many nonresectional methods of in-situ tumor ablation have been recently described. These include alcohol injection, cryotherapy, radiofrequency and intraoperative radiotherapy. Recently more interest has been directed to the use of laser as a source of ablative energy. Laser-induced interstitial thermotherapy is an experimental technique used to destroy tumors within the liver. Initially this was in the form of bare-tipped photocoagulation but the development of a diffuser tip has enabled the formation of larger diameter lesions using heat to produce an area of coagulative necrosis. Less heat is lost if hepatic vascular inflow is occluded during the procedure and consequently a larger area of tumor necrosis is produced. The prospect of a simpler, more efficient system of tumor ablation is attractive so we undertook a review of the current issues surrounding this emerging treatment
    
    
17. 5/8/02 Interstitial laser thermotherapy in the treatment of colorectal liver metastases. J Surg Oncol 2001 Jan;76(1):73-81 PMID: 11223830 Metastatic liver disease is the commonest cause of death in patients with colorectal cancer. A small proportion of these patients (10%) may be treated by surgical resection with five year survival approaching 35-40%.Alternative treatment modalities for localised hepatic disease include in situ ablative techniques that have the advantages of percutaneous application and minimal morbidity. These include Interstitial Laser Thermotherapy (ILT), Radio Frequency Ablation, Percutaneous Microwave therapy, and Focussed Ultrasound Therapy. This article focuses specifically on the development and utilisation of ILT in the treatment of colorectal liver metastases. It provides a review of the pathophysiological factors involved, present status of clinical studies, and future directions. ILT is a safe technique for the treatment of colorectal liver metastases. It may be delivered by minimally invasive techniques to lesions considered unresectable by present criteria. Limitations include the extent and completeness of tumour necrosis achieved as well as imaging techniques. Clinical problems include a lack of controlled studies. Assessment of long-term survival in prospective randomised trials is needed to assess the efficacy of this procedure
    
    
18. 5/8/02 Treatment of hepatocellular carcinoma by percutaneous laser hyperthermia. J Gastroenterol Hepatol 2001 May;16(5):548-52 PMID: 11350552 The majority of patients with hepatocellular carcinoma (HCC) are unsuitable for partial liver resection or transplantation because of unfavorable tumor characteristics or underlying severe liver disease. Techniques of in situ tumor ablation may be an alternative to resection and have the advantage of reduced morbidity and mortality. Percutaneous laser-induced hyperthermia produces predictable areas of tumor necrosis with minimal complications. This study assesses the effectiveness of percutaneous interstitial laser hyperthermia in eight patients with hepatocellular carcinoma occurring on a background of chronic liver disease
    
    

Home